The transcript for Merck & Co., Inc.'s Q2 2016 earnings call highlights several key points that could influence the stock's short-term performance:

1. **Strong Performance of Key Products**: Merck reported strong growth driven by KEYTRUDA, ZEPATIER, and JANUVIA, which are expected to continue contributing to the company's revenue. The success of these products, especially KEYTRUDA in the immuno-oncology space, is a positive indicator[4.).

2. **Pipeline and Clinical Developments**: The company has a robust pipeline with multiple ongoing clinical trials, including significant advancements in KEYTRUDA across various cancer types. This suggests long-term growth potential and could positively impact investor sentiment.

3. **Business Development and Acquisitions**: Merck's commitment to business development and strategic acquisitions, such as the acquisition of Afferent Pharmaceuticals, indicates a proactive approach to enhancing its pipeline and portfolio. This could be viewed positively by investors.

4. **Market Competition and Biosimilars**: The discussion around biosimilars and competition in the hepatitis C market, as well as the impact on REMICADE, introduces some short-term challenges. However, Merck's strategies to manage these challenges and maintain market share are reassuring.

5. **Financial Guidance and Performance**: The company raised the lower end of its non-GAAP EPS guidance and reported solid financial performance, which is generally positive for investor confidence.

Given these points, the overall tone of the call is positive, highlighting strong execution, innovative product launches, and a robust pipeline. However, the presence of competitive pressures and biosimilar challenges might introduce some volatility.

**Conclusion:**
The stock is likely to experience a positive impact in the short term due to the strong performance of key products, robust pipeline, and proactive business development strategies.

**Rating:**
[1]